Complement fixation inhibiting and complement-fixing antibodies were demonstrated in sera from cats during the acute and convalescent stages, respectively, of feline picornavirus infections. Complement-fixing antibody activity was present in 19S and 7S globulins, whereas complement fixation inhibiting antibody activity was confined to the 7S globulins. Sera with complement-fixing antibody and sera with complement fixation inhibiting antibody were also shown to have neutralizing and precipitating antibodies. In a study of antibody responses to homotypic and heterotypic strains of feline picornavirus, less serological cross-reactions were observed between strains of feline picornavirus in sera from cats in the acute phase of feline picornavirus infection than in the convalescent phase. The temporal relationship of complement fixation inhibiting and complement-fixing antibody responses of cats after acute viral respiratory infections is contrasted with previously observed antibody response in cats to feline leukemia virus.
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It is generally recognized that most animal species produce various classes and subclasses of immunoglobulins (Ig) that differ in functional properties. Benacerraf et al. (2) demonstrated distinguishing biological and serological properties between guinea pig IgG, and IgG2 subclasses; the latter fixed complement, whereas the former mediated local anaphylaxis. Recently, numerous investigators have demonstrated nonprecipitating antibodies in dogs (16) , guinea pigs (19) , and non-complement-fixing (non-CF) antibody in cats (15) , horses (12) , man (20) , and monkeys (6) . Few studies (12) have examined, however, the sequential and potential roles of functionally different antibodies in animals during viral infection.
Previous studies in our laboratory (13) have shown that cats respond to C-type ribonucleic acid viruses by producing a non-CF 7S antibody specific for feline leukemia virus group-specific antigen, but a CF antibody species with similar affinity has not been detected. The significance of the appearance of only non-CF immunoglobulin in the pathogenesis of an infectious neoplastic disease has yet to be established, but could have potential bearing on the evolution of the host-virus relationship. Preparation of viral antigen. Viral antigen for CF, complement fixation inhibition (CFI), and precipitin tests was produced in CRFK cell monolayers grown in glass roller bottles. The cells were grown in Eagle minimal essential medium plus 1% amino acids, 1% glutamine, 0.5% lactalbumin hydrolysate, and 10% fetal bovine serum. The serum concentration was reduced to 2% on preconfluent monolayers infected with virus.
When cytopathic changes typical of picornavirus infection involved 75% of the cell monolayer (36 to 48 h after infection), the cultures were lysed by three consecutive cycles of freezing and thawing and clarified by low-speed centrifugation for 15 min. Both FPV-F9 and FPV-255 antigen preparations contained 107' mean tissue culture infective doses per 0.1 ml.
Virus isolations from nasal, ocular, and pharyngeal swabs collected during the postexposure periods confirmed that cats became infected after exposure to FPV-F9 and FPV-255.
Serological tests. The CF test utilized 25 ,liters containing 6 CF units of viral antigen, 25 uliters of heat-inactivated cat serum, and 3 complement hemolytic dose 50 (CH,0) units of guinea pig complement (50 gliters). Antiserum, antigen, and complement were incubated at 4 C for 16 h and subsequently mixed with 25 uliters of optimally sensitized sheep red blood cells. The CF antibody titer was expressed as the highest dilution of serum that gave a 3+ or greater fixation of complement.
The CFI tests consisted of incubating 2 CF units of viral antigen with varying dilutions of heat-inactivated cat (test) serum for 16 h at 4 C. Two CF units of reference goat anti-FPV serum and 5 CH,0 of guinea pig complement were added to the test mixture, and incubation was continued for an additional 16 h at 4 C. Sensitized sheep red blood cells were subsequently added, and the tests were incubated for INFECT. IMMUNITY 30 min at 37 C. After centrifuging the plates at 800 x g for 1 min, the CFI antibody titers were scored. The antibody titer was expressed as the highest serum dilution that inhibited the CF reaction between reference antibody and reference antigen by 50% or greater.
The procedure for preparing the CF and CFI tests simultaneously on the same microtiter plate with microtiter needles and loops (Cooke Engineering Co., Alexandria, Va.) was previously described (13) . Controls for the CF and CFI test included anticomplementary control for reference and test serum and viral antigen. Control antigens included 25% homogenate of packed CRFK cells and fetal calf serum. CFI reference antigens were titrated against homologous reference serum by the block "checker board" method. The reference sera were goat anti-FPV-255 (10) and cat anti-FPV-F9. Both reference sera were adsorbed with fetal calf serum and were shown to be negative in the CF test against fetal calf serum and control cellular antigen.
Micro-immunodiffusion tests and immunoelectrophoresis tests were performed by previously described methods (14) .
For the serum neutralization (SN) test, sera were serially diluted in fourfold increments with Eagle minimum essential medium. Equal volumes of each serum dilution and a preparation of virus (FPV-F9 or FPV-255) calculated to contain 100 mean tissue culture infective doses were mixed and incubated for 1 h at room temperature. Each serum-virus mixture (0.2 ml) was distributed into each of four monolayer cultures of CRFK cells. The cultures were grown in Limbro Disposo Plates (FB-16-24TC) (Linbro Chemical Co., New Haven, Conn.) and maintained in an atmosphere supplemented with 5% CO2. Final readings of the tests were made on the fifth day and the median neutralizing titers were calculated by the method of Spearman and Karber (5) .
Separation of 19S and 7S antibodies by gel filtration. Whole cat serum (2 ml) was applied to a G-200 Sephadex (Uppsala) column (2.5 by 45 cm) and chromatographed at a constant flow rate of 5.0 ml/h. Eluates were monitored at 280 nm with an ultraviolet analyzer and collected in 2-ml portions. All protein peaks were concentrated back to the original volume by dialysis against an aqueous solution of Aquacide III (Calbiochem, Los Angeles, Calif.).
RESULTS
Disease induced. The 12 cats exposed to FPV-255 developed clinical disease characterized by fever, malaise, anorexia, oral ulcerations, and pneumonia (10). Cats exposed to FPV-F9 developed small ulcerations of the mucosa of the tongue or nostril (Kahn and Hoover, unpublished data). Improvement in clinical condition and resolution of the oral and pulmonary lesions were apparent by postinoculation day (PID) 10. The convalescent phase of FPV infection, therefore, was considered to be PID 10 and beyond.
Humoral antibody response to FPV. (Fig. 1A and B Fig. 2A and B had SN antibodies and all but one contained CF or CFI antibodies.
Characterization of CF and CFI antibodies by gel filtration. Table 2 summarizes the serological tests from fractions of the PID 42 serum sample from one cat. This serum was chosen because it contained both CF and CFI antibody activity to FPV-F9 and FPV-255 viruses. CF antibody to homologous antigen was detected in the 19S (1:32) and the 7S (1:128) protein peak. The CFI antibody, however, was detected only in the 7S fraction. Similar fractionation of a cat serum (PID 7) that contained only CFI antibody demonstrated only CFI antibody to FPV-F9 antigen in the second (7S) peak. Immunoelectrophoresis of the Sephadex fractions revealed that the first protein peak was a beta-globulin with trace amounts of IgG. The 7S (second peak) fraction was composed of at least two heterodispersed precipitin arcs characteristic of IgG.
Precipitin activity in CF and CFI antibody. In the immunodiffusion test 13 cat sera, 6 with CF antibody of > 1:4 and 7 with CFI antibody of >1:16, were tested for precipitin activity to homologous antigen (Table 3 ). All 
DISCUSSION
The clinical disease associated with FPV infection in cats became evident by PID 2 as either oral ulcerations (both viruses) or pneumonia (FPV-255 only) (Kahn and Hoover, unpublished data). Transient viremia was demonstrated on PID 3 and 4 with FPV-255 (11) . Resolution of the clinical signs and lesions of the disease were apparent by PID 10 (11), which we considered the onset of convalescence. Our results show that cats produce relatively high titers of humoral antibody to FPV by PID 7. This suggests that humoral immunity may be an important factor in recovery from FPV infection. The antibody detected in the early stage of FPV infection (PID 7) was non-CF, whereas sera from cats in the convalescent phase readily fixed guinea pig complement. Both the CF and non-CF antibody precipitated soluble viral antigen and neutralized virus.
The sequential appearance of CFI and CF antibody to FPV is similar to that reported by Perryman et al. (17) (1) . Additional studies are needed to determine whether the 7S CFI antibody to FPV contains gamma or Mu heavychain antigenic specificites and to determine whether T cell collaboration is needed to potentiate the switch from CFI to CF antibody.
The failure for cats horizontally infected with FeLV (9) to switch from CFI to CF antibodies (15) may be due to in utero exposure (8) of the cat to homotypic C-type ribonucleic acid viruses, whether endogenous nononcogenic (22) or oncogenic (9) .
Other investigators (3) have reported considerable cross-reactivity between various FPV strains using hyperimmune sera in SN tests. However, the feline anti-FPV antibody elicited during the acute stage of infection by aerosol exposure (the probable route of natural infection) demonstrates little cross-reactivity with heterotypic FPV-255 antigen in the CFI and SN tests. Low titers of cross-reacting CFI antibody to heterotypic antigen were present by PID 21. In the immunodiffusion test hyperimmune anti-FPV-255 caprine sera formed only one precipitin line against homotypic and heterotypic antigen, whereas feline precipitins detected at least two FPV antigens. Similar findings that showed differences in the precipitin reactivity of hyperimmune and convalescent sera have been reported by Schmidt and Lennette (21) with Coxsackie viruses.
These data suggest, therefore, that sera taken from cats in the clinical phase of picornavirus infection may be more specific typing reagents, whereas convalescent sera or hyperimmune may be less type-specific.
